MajuMathewsMD

PubMed

• 5 citations
  Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.
  Dong-Jing Fu, Qiaoyi Zhang, Ling Shi, Stephane Borentain, Shien Guo, Maju Mathews, Joana Anjo, Abigail I Nash, Marguerite O'Hara, Carla M Canuso> ;BMC Psychiatry. 2023 Aug 11
• 2 citations
  Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
  Stephane Borentain, Pooja Desai, Dong-Jing Fu, Li Nancy Chen, Rosanne Lane, Maju Mathews, Carla M Canuso> ;Journal of Psychopharmacology. 2023 Aug 1
• 1 citations
  Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission ...
  Qiaoyi Zhang, Marguerite O'Hara, Carter McCormick, Melissa Lingohr-Smith, Stephane Borentain, Maju Mathews, Kruti Joshi, Joana Anjo, Jay Lin> ;Journal of Medical Economics. 2022 Jan 20
• 2 citations
  Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression.
  Joachim Morrens, Maju Mathews, Vanina Popova, Stephane Borentain, Benoit Rive, Beatriz Gonzalez Martin Moro, Carol Jamieson, Qiaoyi Zhang> ;Neuropsychiatric Disease and Treatment. 2022 Jan 1
• 3 citations
  Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
  Stephane Borentain, David Williamson, Ibrahim Turkoz, Vanina Popova, William V McCall, Maju Mathews, Frank Wiegand> ;Neuropsychiatric Disease and Treatment. 2021 Nov 1
• 9 citations
  Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health ...
  Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, A. Godet, Katalin Pungor, Srihari Gopal> ;Patient Preference and Adherence. 2021 Oct 2
• 9 citations
  Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Beh...
  Bettina Diekamp, Stephane Borentain, Dong-Jing Fu, Robert Murray, Kristin Heerlein, Qiaoyi Zhang, Cornelius Schüle, Maju Mathews> ;Neuropsychiatric Disease and Treatment. 2021 Jul 15
• 5 citations
  Comments to Drs. Bahji, Vazquez, and Zarate.
  Wayne C. Drevets, Vanina Popova, Stephane Borentain, Rosanne Lane, M. Soledad Cepeda, Maju Mathews, Husseini K. Manji, Carla M. Canuso> ;Journal of Affective Disorders. 2021 Mar 15
• 5 citations
  Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.
  Rebekka Lencer, María Paz García-Portilla, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor> ;Comprehensive Psychiatry. 2021 Mar 2
• 59 citations
  Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
  Christoph U. Correll, Edward Kim, Jennifer Kern Sliwa, Wayne Hamm, Srihari Gopal, Maju Mathews, Raja Venkatasubramanian, Stephen R. Saklad> ;CNS Drugs. 2021 Jan 1
• 3 citations
  Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on ou...
  Katalin Pungor, Vasilis P. Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller, Paul Bergmans> ;Therapeutic Advances in Psychopharmacology. 2020 Dec 23
• 5 citations
  Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
  Martin Lambert, Pedro M. Sanchez, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor> ;Neuropsychiatric Disease and Treatment. 2020 Dec 23
• 14 citations
  Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
  Brianne Brown, Ibrahim Turkoz, Branislav Mancevski, Maju Mathews> ;Early Intervention in Psychiatry. 2020 Aug 1
• 27 citations
  Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.
  Clifton Blackwood, Panna Sanga, Isaac Nuamah, Alexander Keenan, Arun Singh, Maju Mathews, Srihari Gopal> ;Patient Preference and Adherence. 2020 Jul 2
• 11 citations
  Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatme...
  Maju Mathews, Srihari Gopal, Arun Singh, Isaac Nuamah, Katalin Pungor, Wilson Tan, Bernardo Soares, Edward Kim, Adam Savitz> ;Neuropsychiatric Disease and Treatment. 2020 Jun 19
• 5 citations
  Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui.
  Maju Mathews, Ella Daly, Vanina Popova, Kristin Heerlein, Carla M. Canuso, Wayne C. Drevets> ;Epidemiology and Psychiatric Sciences. 2020 Apr 29
• 2 citations
  Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
  Srihari Gopal, Jagadish Gogate, Katalin Pungor, Edward Kim, Arun Singh, Maju Mathews> ;Neuropsychiatric Disease and Treatment. 2020 Mar 6
• 26 citations
  Approval of esketamine for treatment-resistant depression
  Jaskaran Singh, Ella Daly, Maju Mathews, Maggie Fedgchin, Vanina Popova, David Hough, Wayne C. Drevets> ;The Lancet. Psychiatry. 2020 Mar 1
• 4 citations
  Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations
  Alberto Russu, Adam Savitz, Maju Mathews, Srihari Gopal, Yu Feng, Mahesh N. Samtani> ;Journal of Clinical Psychopharmacology. 2019 Nov 1
• 3 citations
  A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics
  Nan Li, Jian Min Zhuo, Ibrahim Turkoz, Maju Mathews, Yu Feng, Wilson Tan> ;Expert Opinion on Pharmacotherapy. 2019 Aug 8
• 22 citations
  Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
  Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam Savitz, Edward Kim, Wilson Tan, Bernardo Soares, Christoph U. Correll> ;Neuropsychiatric Disease and Treatment. 2019 May 21
• 5 citations
  Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 ran...
  Adam Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews, Bernardo Soares> ;Revista Brasileira De Psiquiatria. 2019 Apr 15
• 4 citations
  Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.
  Abigail I. Nash, Ibrahim Turkoz, Adam Savitz, Maju Mathews, Edward Kim> ;Neuropsychiatric Disease and Treatment. 2019 Mar 22
• 4 citations
  Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
  Maju Mathews, Isaac Nuamah, Adam Savitz, David Hough, Dean Najarian, Edward Kim, Srihari Gopal> ;Neuropsychiatric Disease and Treatment. 2018 Oct 25
• 6 citations
  Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post ...
  Maju Mathews, Huiling Pei, Adam Savitz, Isaac Nuamah, David Hough, Larry Alphs, Srihari Gopal> ;Clinical Drug Investigation. 2018 Aug 1
• Join now to see all